General Information of Drug (ID: DMPIFLA)

Drug Name
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine Drug Info
Synonyms 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine; 4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5328819
TTD Drug ID
DMPIFLA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [2]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [3]
Gefitinib DM15F0X Colon adenocarcinoma Approved [4]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [5]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [6]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [7]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [8]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [9]
Epidermal growth factor DMVONE6 Vulnerary ND56.Z Approved [7]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AFQ056 DMMHSLC Fragile X syndrome LD55 Phase 2/3 [11]
ADX-48621 DM6GTMD Parkinson disease 8A00.0 Phase 2/3 [12]
RG-7090 DMX8JYN Fragile X syndrome LD55 Phase 2 [13]
STX-107 DMLNKX7 Autism spectrum disorder 6A02 Phase 2 [14]
ADX10059 DMGVKHQ Anxiety disorder 6B00-6B0Z Phase 2 [15]
McN3377 DMTCADJ Fragile X syndrome LD55 Phase 1/2 [16]
MK-3328 DMW2O5D Alzheimer disease 8A20 Phase 1 [17]
[3H]fenobam DMBOXA1 Allodynia MB40.1 Phase 1 [18]
RG7342 DMIW5NG Schizophrenia 6A20 Phase 1 [19]
BMS-984923 DMFNDUL Alzheimer disease 8A20 Phase 1 [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [1]
Metabotropic glutamate receptor 5 (mGluR5) TTHS256 GRM5_HUMAN Inhibitor [1]

References

1 Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
2 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
3 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
4 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
5 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
6 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
8 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
9 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
10 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
11 Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
12 Pipeline of Addex Pharma. Addex Pharma. 2009.
13 The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
14 Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
15 A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
16 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
18 Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
19 Clinical pipeline report, company report or official report of Roche.
20 Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88.